Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
Endocrinology ; 151(6): 2788-99, 2010 Jun.
Article in English | MEDLINE | ID: mdl-20332198

ABSTRACT

The injection of equine chorionic gonadotropin (eCG) in dairy goats induces the production of anti-eCG antibodies (Abs) in some females. We have previously shown that Abs negatively modulate the LH and FSH-like bioactivities of eCG, in most cases, compromising fertility in treated females. Surprisingly, we found out that some anti-eCG Abs improved fertility and prolificity of the treated females, in vivo. These Abs, when complexed with eCG, enhanced LH and FSH ability to induce steroidogenesis on specific target cells, in vitro. In the present study, we analyzed the impact of three eCG/anti-eCG Ab-enhancing complexes on two transduction mechanisms triggered by the FSH receptor: guanine nucleotide-binding protein alphaS-subunit/cAMP/protein kinase A (PKA) and beta-arrestin-dependent pathways, respectively. In all cases, significant enhancing effects were observed on ERK phosphorylation compared with eCG alone. However, cAMP production and PKA activation induced by eCG could be differently modulated by Abs. By using a pharmacological inhibitor of PKA and small interfering RNA-mediated knock-down of endogenous beta-arrestin 1 and 2, we demonstrated that signaling bias was induced and was clearly dependent on the complexed Ab. Together, our data show that eCG/anti-eCG Ab-enhancing complexes can differentially modulate cAMP/PKA and beta-arrestin pathways as a function of the complexed Ab. We hypothesize that enhancing Abs may change the eCG conformation, the immune complex acquiring new "biased" pharmacological properties ultimately leading to the physiological effects observed in vivo. The modulation of ligand pharmacological properties by Abs opens promising research avenues towards the optimization of glycoprotein hormone biological activities and, more generally, the development of new therapeutics.


Subject(s)
Antibodies/immunology , Antigen-Antibody Complex/pharmacology , Chorionic Gonadotropin/immunology , Follicle Stimulating Hormone/metabolism , Gonadotropins, Equine/immunology , Signal Transduction/drug effects , Antigen-Antibody Complex/immunology , Arrestins/metabolism , Cell Line , Cyclic AMP/metabolism , Enzyme-Linked Immunosorbent Assay , Female , Fluorescence Resonance Energy Transfer , Humans , Isoquinolines/pharmacology , Kinetics , Mitogen-Activated Protein Kinase 1/metabolism , Mitogen-Activated Protein Kinase 3/metabolism , Phosphorylation/drug effects , RNA, Small Interfering , Sulfonamides/pharmacology , beta-Arrestin 1 , beta-Arrestins
2.
Mol Endocrinol ; 24(3): 561-73, 2010 Mar.
Article in English | MEDLINE | ID: mdl-20107152

ABSTRACT

Deglycosylated FSH is known to trigger poor Galphas coupling while efficiently binding its receptor. In the present study, we tested the possibility that a deglycosylated equine LH (eLHdg) might be able to selectively activate beta-arrestin-dependent signaling. We compared native eLH to an eLH derivative [i.e. truncated eLHbeta (Delta121-149) combined with asparagine56-deglycosylated eLHalpha (eLHdg)] previously reported as an antagonist of cAMP accumulation at the FSH receptor (FSH-R). We confirmed that, when used in conjunction with FSH, eLHdg acted as an antagonist for cAMP accumulation in HEK-293 cells stably expressing the FSH-R. Furthermore, when used alone at concentrations up to 1 nM, eLHdg had no detectable agonistic activity on cAMP accumulation, protein kinase A activity or cAMP-responsive element-dependent transcriptional activity. At higher concentrations, however, a weak agonistic action was observed with eLHdg, whereas eLH led to robust responses whatever the concentration. Both eLH and eLHdg triggered receptor internalization and led to beta-arrestin recruitment. Both eLH and eLHdg triggered ERK and ribosomal protein (rp) S6 phosphorylation at 1 nM. The depletion of endogenous beta-arrestins had only a partial effect on eLH-induced ERK and rpS6 phosphorylation. In contrast, ERK and rpS6 phosphorylation was completely abolished at all time points in beta-arrestin-depleted cells. Together, these results show that eLHdg has the ability to preferentially activate beta-arrestin-dependent signaling at the FSH-R. This finding provides a new conceptual and experimental framework to revisit the physiological meaning of gonadotropin structural heterogeneity. Importantly, it also opens a field of possibilities for the development of selective modulators of gonadotropin receptors.


Subject(s)
Arrestins/metabolism , Luteinizing Hormone/analogs & derivatives , Receptors, FSH/metabolism , Signal Transduction/drug effects , Animals , Blotting, Western , Cattle , Cell Line , Cyclic AMP-Dependent Protein Kinases/metabolism , Enzyme Activation/drug effects , Female , Horses , Humans , Immunoprecipitation , Luteinizing Hormone/chemistry , Luteinizing Hormone/metabolism , Luteinizing Hormone/pharmacology , Mice , Phosphorylation/drug effects , Protein Binding , Protein Transport/drug effects , RNA, Small Interfering , Receptors, FSH/agonists , Receptors, FSH/antagonists & inhibitors , Ribosomal Protein S6/metabolism , Swine , beta-Arrestins
3.
Mol Cell Endocrinol ; 315(1-2): 271-6, 2010 Feb 05.
Article in English | MEDLINE | ID: mdl-19778579

ABSTRACT

Follicle-stimulating hormone (FSH) controls the proliferation and differentiation of Sertoli cells of the testis. FSH binds a G protein-coupled receptor (GPCR) to stimulate downstream effectors of the phosphoinositide-3 kinase (PI3K)-dependent pathway, without enhancing PI3K activity. To clarify this paradox, we explored the activity of phosphatase and tensin homolog deleted in chromosome 10 (PTEN), the PI3K major regulator, in primary cultures of rat Sertoli cells. We show that, within minutes, FSH increases PTEN neo-synthesis, requiring the proteasomal degradation of an unidentified intermediate, as well as PTEN enzymatic activity. Importantly, introducing an antisense cDNA of PTEN into differentiating Sertoli cells restores FSH-dependent cell proliferation. In conclusion, these results provide a new mechanism of PTEN regulation, which could serve to block entry into S phase of Sertoli cells, while they are proceeding through differentiation in prepubertal animals.


Subject(s)
Follicle Stimulating Hormone/pharmacology , Mitosis/drug effects , PTEN Phosphohydrolase/metabolism , Puberty/physiology , Sertoli Cells/drug effects , Sertoli Cells/physiology , Animals , Cells, Cultured , Follicle Stimulating Hormone/metabolism , Humans , Male , Mitosis/physiology , PTEN Phosphohydrolase/genetics , Phosphatidylinositol 3-Kinases/metabolism , Phosphatidylinositols/metabolism , Rats , Rats, Wistar , Sertoli Cells/cytology , Swine , Transferrin/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL
...